Aptevo Therapeutics Inc (APVO) - Net Assets
Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has net assets worth $11.61 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.90 Million) and total liabilities ($8.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APVO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.61 Million |
| % of Total Assets | 58.35% |
| Annual Growth Rate | -14.27% |
| 5-Year Change | 1329.36% |
| 10-Year Change | -65.63% |
| Growth Volatility | 407.12 |
Aptevo Therapeutics Inc - Net Assets Trend (2014–2025)
This chart illustrates how Aptevo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Aptevo Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual net assets of Aptevo Therapeutics Inc from 2014 to 2025. For live valuation and market cap data, see Aptevo Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $17.38 Million | +265.53% |
| 2024-12-31 | $4.75 Million | -61.09% |
| 2023-12-31 | $12.22 Million | -32.01% |
| 2022-12-31 | $17.97 Million | +1378.13% |
| 2021-12-31 | $1.22 Million | -92.67% |
| 2020-12-31 | $16.59 Million | +40.13% |
| 2019-12-31 | $11.84 Million | -61.05% |
| 2018-12-31 | $30.41 Million | -62.94% |
| 2017-12-31 | $82.03 Million | +62.23% |
| 2016-12-31 | $50.57 Million | -42.94% |
| 2015-12-31 | $88.62 Million | -6.33% |
| 2014-12-31 | $94.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aptevo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10244400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $114.00K | 0.66% |
| Other Components | $292.38 Million | 1682.19% |
| Total Equity | $17.38 Million | 100.00% |
Aptevo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aptevo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABAS Protect AB
ST:ABAS
|
$5.66 Million |
|
Terra Uranium Ltd
AU:T92
|
$5.67 Million |
|
RH Bophelo Ltd
JSE:RHB
|
$5.67 Million |
|
AIxCrypto Holdings, Inc.
NASDAQ:AIXC
|
$5.68 Million |
|
NV Gold Corp
V:NVX
|
$5.66 Million |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
$5.66 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
$5.65 Million |
|
Volato Group Inc.
NYSE MKT:SOAR
|
$5.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aptevo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,755,000 to 17,381,000, a change of 12,626,000 (265.5%).
- Net loss of 25,967,000 reduced equity.
- Dividend payments of 1,571,000 reduced retained earnings.
- New share issuances of 37,940,000 increased equity.
- Other factors increased equity by 2,224,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.97 Million | -149.4% |
| Dividends Paid | $1.57 Million | -9.04% |
| Share Issuances | $37.94 Million | +218.28% |
| Other Changes | $2.22 Million | +12.8% |
| Total Change | $- | 265.53% |
Book Value vs Market Value Analysis
This analysis compares Aptevo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $2129851.42 | $4.54 | x |
| 2015-12-31 | $1996800.36 | $4.54 | x |
| 2016-12-31 | $1539.02 | $4.54 | x |
| 2017-12-31 | $2368.56 | $4.54 | x |
| 2018-12-31 | $616004.86 | $4.54 | x |
| 2019-12-31 | $1850312.50 | $4.54 | x |
| 2020-12-31 | $2865975.82 | $4.54 | x |
| 2021-12-31 | $152000.00 | $4.54 | x |
| 2022-12-31 | $2063605.05 | $4.54 | x |
| 2023-12-31 | $585296.93 | $4.54 | x |
| 2024-12-31 | $6199.07 | $4.54 | x |
| 2025-12-31 | $5509.03 | $4.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aptevo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.56x
- Recent ROE (-149.40%) is above the historical average (-333.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -54.03% | -112.02% | 0.38x | 1.27x | $-60.58 Million |
| 2015 | -66.94% | -176.53% | 0.30x | 1.27x | $-68.18 Million |
| 2016 | -222.31% | -308.54% | 0.40x | 1.82x | $-117.47 Million |
| 2017 | 8.50% | 47.57% | 0.13x | 1.43x | $-1.23 Million |
| 2018 | -176.57% | -232.75% | 0.34x | 2.22x | $-56.73 Million |
| 2019 | -377.45% | -137.85% | 0.61x | 4.51x | $-45.88 Million |
| 2020 | -106.97% | -411.93% | 0.08x | 3.23x | $-19.41 Million |
| 2021 | -2246.13% | -222.20% | 0.22x | 46.55x | $-27.43 Million |
| 2022 | 44.66% | 257.77% | 0.09x | 1.90x | $6.23 Million |
| 2023 | -142.47% | 0.00% | 0.00x | 2.03x | $-18.63 Million |
| 2024 | -507.47% | 0.00% | 0.00x | 3.28x | $-24.61 Million |
| 2025 | -149.40% | 0.00% | 0.00x | 1.56x | $-27.71 Million |
Industry Comparison
This section compares Aptevo Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aptevo Therapeutics Inc (APVO) | $11.61 Million | -54.03% | 0.71x | $5.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more